Probiotic
    Moderate Evidence

    Bacillus Coagulans

    Weizmannia (Bacillus) coagulans

    TL;DR

    A spore-forming probiotic that survives stomach acid and room-temperature storage without refrigeration. The best evidence is for IBS symptoms and abdominal bloating, with smaller signals for constipation and protein absorption. Strain matters more than the species name: GBI-30 6086 and MTCC 5856 carry most of the trial data.

    Ideal For

    • IBS with bloating or loose stools
    • Travellers who cannot refrigerate a probiotic
    • People who react badly to standard Lactobacillus blends

    Avoid If

    • You are significantly immunocompromised
    • You have a central venous catheter
    • You are critically ill or hospitalised

    Overview

    Bacillus coagulans (recently reclassified as Weizmannia coagulans) is unusual among probiotics because it forms a protective endospore. That spore survives gastric acid, bile, and warehouse temperatures, which solves the two biggest practical problems with Lactobacillus and Bifidobacterium products: delivery and shelf stability. It germinates in the small intestine, produces L(+) lactic acid, and is largely cleared within a week or two of stopping.

    The clinical file is modest but real. Randomised trials of the MTCC 5856 strain in diarrhoea-predominant IBS reported meaningful reductions in bloating, stool frequency, and abdominal pain over 90 days. The GBI-30 6086 strain has trials in general abdominal discomfort and gas, in post-exercise recovery, and in improving amino acid absorption when co-administered with protein. Effect sizes are moderate, and most trials are industry-sponsored — a common limitation across the probiotic literature that should temper enthusiasm without dismissing the findings.

    What it is not is a broad gut-flora reset. Because it is transient, it does not colonise. Benefits typically fade within a few weeks of stopping, which means it is best judged with a defined 8-12 week trial against a specific symptom rather than taken indefinitely on faith.

    How It Works

    • Spore coat protects the organism through gastric acid, allowing far higher live delivery to the small intestine than most vegetative probiotics
    • Produces L(+) lactic acid and bacteriocins that lower luminal pH and suppress some pathogenic species
    • Modulates gut-associated lymphoid tissue, shifting cytokine balance toward reduced local inflammation
    • Improves proteolysis in the small intestine, which underpins the amino acid absorption findings
    • Transient coloniser: cleared within roughly 7-14 days of the last dose

    Benefits & Outcomes

    No linked outcomes yet. Research is ongoing.

    Health Concerns Addressed

    IBS (Irritable Bowel Syndrome)

    condition
    Likely effective
    Moderate Evidence
    Effectiveness 7/5

    Two 90-day randomised trials of the MTCC 5856 strain found clinically meaningful reductions in bloating, stool frequency, and abdominal pain in diarrhoea-predominant IBS. Effect sizes are moderate and the trials are industry-linked, but the spore form solves the delivery problem that undermines many probiotic studies.

    Supporting Research
    8 studies

    Efficacy of a synbiotic containing Bacillus coagulans in the treatment of irritable bowel syndrome: a randomized placebo-controlled trial

    Score: 5/10
    2014
    rct
    n=85

    Rogha M, Esfahani MZ, Zargarzadeh AH

    Abdominal pain and bloating improved significantly in the synbiotic group versus placebo, with no difference in some secondary measures.

    View source

    Bacillus coagulans MTCC 5856 supplementation in the management of diarrhea predominant irritable bowel syndrome: a double blind randomized placebo controlled pilot clinical study

    Score: 5/10
    2016
    rct
    n=36

    Majeed M, Nagabhushanam K, Natarajan S +5 more

    Clinical symptom scores, bloating and stool frequency improved significantly versus placebo.

    View source

    Randomized clinical trial: the effect of probiotic Bacillus coagulans Unique IS2 vs. placebo on the symptoms management of irritable bowel syndrome in adults

    Score: 7/10
    2019
    rct
    n=153

    Madempudi RS, Ahire JJ, Neelamraju J +2 more

    Abdominal pain, bloating and stool frequency improved significantly versus placebo, with a higher rate of overall symptom relief.

    View source

    Bacillus coagulans as a potent intervention for treating irritable bowel syndrome: A systematic review and meta-analysis of randomized controlled trials

    Score: 6/10
    2023
    meta_analysis

    AbdelQadir YH, Nabhan AI, Althawadi Y +2 more

    Pooled RCT data showed B. coagulans improved global IBS symptom scores and abdominal pain compared with placebo.

    View source

    Efficacy of Probiotics for Irritable Bowel Syndrome: A Systematic Review and Network Meta-Analysis

    Score: 8/10
    2022
    meta_analysis
    n=5531

    Zhang T, Zhang C, Zhang J +2 more

    B.coagulans exhibited the highest probability to be the optimal probiotic specie in improving IBS symptom relief rate, as well as global symptom, abdominal pain, bloating, and straining scores.

    View source

    Bacillus coagulans significantly improved abdominal pain and bloating in patients with IBS

    Score: 5/10
    2009
    rct
    n=44

    Hun L

    Bacillus coagulans GBI-30, 6086 significantly reduced abdominal pain and bloating scores versus placebo over 8 weeks in IBS patients.

    View source

    Effects of a proprietary Bacillus coagulans preparation on symptoms of diarrhea-predominant irritable bowel syndrome

    Score: 4/10
    2009
    rct
    n=52

    Dolin BJ

    Patients receiving GanedenBC30 had fewer daily bowel movements than placebo in diarrhea-predominant IBS in this controlled pilot study.

    View source

    Outcome-Specific Efficacy of Different Probiotic Strains and Mixtures in Irritable Bowel Syndrome: A Systematic Review and Network Meta-Analysis

    Score: 7/10
    2023
    meta_analysis

    Zhang T, et al.

    Network meta-analysis ranked probiotic strains by outcome; efficacy was strain- and outcome-specific and no single strain dominated across endpoints.

    View source

    Safety Information

    Potential Side Effects

    Mild gas or transient bloating in the first week is the most common complaint. Serious adverse events are rare in trials.

    Contraindications

    Caution in significant immunosuppression, central venous catheters, or critical illness, where any live organism carries a small bacteraemia risk.

    Drug Interactions

    • Immunosuppressants
    • Systemic antifungals (theoretical)

    Pregnancy & Breastfeeding

    Pregnancy: insufficient_data

    Breastfeeding: insufficient_data

    Dosage Guidelines

    Dosage Used in Studies

    Consult healthcare provider

    Best Time to Take

    Once daily, consistent time

    Best Form

    Strain-identified capsule (GBI-30 6086 or MTCC 5856)

    Bioavailability

    High survival through gastric transit due to the endospore; germinates in the small intestine.

    Food & Timing

    Any time of day, with or without food. The spore form removes the usual need to dose away from meals.

    Medical Disclaimer

    The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.

    Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.